NFX

Nuformix raises £210,000 to advance NXP002 and US Orphan Drug Application

Nuformix plc (LON:NFX) aims to raise £210,000 through a conditional placing to advance its NXP002 inhalation treatment for IPF and PPF...

Nuformix to present NXP002 data at ATS 2025

Nuformix plc will showcase groundbreaking results on NXP002 at the American Thoracic Society Congress in San Francisco, addressing fibrosis and oncology challenges...

Nuformix advancing IPF treatment with NXP002 orphan drug designation (LON:NFX)

Nuformix Plc's Dr. Dan Gooding discusses the EMA's positive orphan drug designation for NXP002, highlighting its significance in treating idiopathic pulmonary fibrosis...

Nuformix advances NXP002 as EMA backs Orphan Drug status

Nuformix plc (LON:NFX) reports promising developments in its drug NXP002 for treating fibrotic lung diseases, highlighting significant operational and financial insights...

Nuformix Plc, EMA Backs Orphan Status for NXP002 in Pulmonary Fibrosis Breakthrough (Video)

Executive Director Dr Dan Gooding outlines how this validation not only highlights the urgent unmet need in IPF but also sharpens Nuformix’s commercial edge with 10 years of market exclusivity and accelerated development support..

Nuformix secures positive EMA opinion for orphan drug status in IPF

Nuformix plc (LON:NFX) has received a positive opinion from the EMA for Orphan Drug Designation of NXP002 in treating Idiopathic Pulmonary Fibrosis (IPF)...

Nuformix updates Registered Office and Company Secretary

Nuformix plc (LON:NFX) has, effective immediately, relocated its registered office to a new London address and appointed Shaun Zulafqar as Company Secretary...

Nuformix reports positive NXP002 results in lung disease models

Nuformix plc announces promising re-analysis results for NXP002, targeting unmet needs in fibrosis and oncology, offering insights into new treatment pathways...

Nuformix advances NXP002 programme with £168,750 Placing

Nuformix plc (LON:NFX) raises £168,750 for fibrosis drug development through a new share placing, advancing its NXP002 programme and corporate goals...

Nuformix plc Annual Results for the period ended 30 September 2024

Nuformix plc (LON:NFX) targets unmet needs in fibrosis and oncology via drug repurposing, focusing on partnering its NXP002 lead program for IPF and PPF...

Nuformix submits NXP002 Orphan Drug Designation Application to EMA

Nuformix plc (LON:NFX) advances NXP002 for Idiopathic Pulmonary Fibrosis, applying for Orphan Drug Designation with European Medicines Agency...

Nuformix submits NXP002 Orphan Drug Designation draft application

Nuformix plc targets fibrosis and oncology needs through drug repurposing, submitting a draft for EMA Orphan Drug Designation for NXP002 in IPF...

Nuformix Executive Director discusses patent updates, interim results and future plans (LON:NFX)

Nuformix plc (LON:NFX) Executive Director Dr. Dan Gooding reveals insights on new patents for NXP002 & NXP004, interim results, and future plans in an exclusive interview...

Nuformix Secures Key Patents and Outlines Future Plans for NXP002 and NXP004 (VIDEO)

Nuformix Plc provides a patent update for its NXP002 and NXP004 programs in fibrosis and oncology. Learn more in this interview with Executive Director Dr. Dan Gooding...

Nuformix continues to advance and exploit current assets within the portfolio

Nuformix plc (LON:NFX) announces unaudited results for the six months ended 31 March 2024, highlighting progress in drug repurposing for fibrosis and oncology...

Nuformix updates on patents grants for NXP002 & NXP004

Nuformix plc (LON:NFX) announces patent updates for NXP002 and NXP004, highlighting advancements in IPF treatment and cocrystal development...

Nuformix to raise £150,000 for NXP002 programme

Nuformix plc (LON:NFX) to raise £150,000 through a subscription for 75,000,000 new ordinary shares to fund the NXP002 programme for idiopathic pulmonary fibrosis...
Search

Funds

NFX

Nuformix raises £210,000 to advance NXP002 and US Orphan Drug Application

Nuformix plc (LON:NFX) aims to raise £210,000 through a conditional placing to advance its NXP002 inhalation treatment for IPF and PPF...

Nuformix to present NXP002 data at ATS 2025

Nuformix plc will showcase groundbreaking results on NXP002 at the American Thoracic Society Congress in San Francisco, addressing fibrosis and oncology challenges...

Nuformix advancing IPF treatment with NXP002 orphan drug designation (LON:NFX)

Nuformix Plc's Dr. Dan Gooding discusses the EMA's positive orphan drug designation for NXP002, highlighting its significance in treating idiopathic pulmonary fibrosis...

Nuformix advances NXP002 as EMA backs Orphan Drug status

Nuformix plc (LON:NFX) reports promising developments in its drug NXP002 for treating fibrotic lung diseases, highlighting significant operational and financial insights...

Nuformix Plc, EMA Backs Orphan Status for NXP002 in Pulmonary Fibrosis Breakthrough (Video)

Executive Director Dr Dan Gooding outlines how this validation not only highlights the urgent unmet need in IPF but also sharpens Nuformix’s commercial edge with 10 years of market exclusivity and accelerated development support..

Nuformix secures positive EMA opinion for orphan drug status in IPF

Nuformix plc (LON:NFX) has received a positive opinion from the EMA for Orphan Drug Designation of NXP002 in treating Idiopathic Pulmonary Fibrosis (IPF)...

Nuformix updates Registered Office and Company Secretary

Nuformix plc (LON:NFX) has, effective immediately, relocated its registered office to a new London address and appointed Shaun Zulafqar as Company Secretary...

Nuformix reports positive NXP002 results in lung disease models

Nuformix plc announces promising re-analysis results for NXP002, targeting unmet needs in fibrosis and oncology, offering insights into new treatment pathways...

Nuformix advances NXP002 programme with £168,750 Placing

Nuformix plc (LON:NFX) raises £168,750 for fibrosis drug development through a new share placing, advancing its NXP002 programme and corporate goals...

Nuformix plc Annual Results for the period ended 30 September 2024

Nuformix plc (LON:NFX) targets unmet needs in fibrosis and oncology via drug repurposing, focusing on partnering its NXP002 lead program for IPF and PPF...

Nuformix submits NXP002 Orphan Drug Designation Application to EMA

Nuformix plc (LON:NFX) advances NXP002 for Idiopathic Pulmonary Fibrosis, applying for Orphan Drug Designation with European Medicines Agency...

Nuformix submits NXP002 Orphan Drug Designation draft application

Nuformix plc targets fibrosis and oncology needs through drug repurposing, submitting a draft for EMA Orphan Drug Designation for NXP002 in IPF...

Nuformix Executive Director discusses patent updates, interim results and future plans (LON:NFX)

Nuformix plc (LON:NFX) Executive Director Dr. Dan Gooding reveals insights on new patents for NXP002 & NXP004, interim results, and future plans in an exclusive interview...

Nuformix Secures Key Patents and Outlines Future Plans for NXP002 and NXP004 (VIDEO)

Nuformix Plc provides a patent update for its NXP002 and NXP004 programs in fibrosis and oncology. Learn more in this interview with Executive Director Dr. Dan Gooding...

Nuformix continues to advance and exploit current assets within the portfolio

Nuformix plc (LON:NFX) announces unaudited results for the six months ended 31 March 2024, highlighting progress in drug repurposing for fibrosis and oncology...

Nuformix updates on patents grants for NXP002 & NXP004

Nuformix plc (LON:NFX) announces patent updates for NXP002 and NXP004, highlighting advancements in IPF treatment and cocrystal development...

Nuformix to raise £150,000 for NXP002 programme

Nuformix plc (LON:NFX) to raise £150,000 through a subscription for 75,000,000 new ordinary shares to fund the NXP002 programme for idiopathic pulmonary fibrosis...
Search

Funds

NFX

FTSE 100

Funds